Scott & White Healthcare study aimed at T-cell lymphoma

Jul 15, 2010

Scott & White's Cancer Research Institute (CRI) is conducting a clinical trial that targets malignant T-cell lymphoma, a type of blood cancer.

Lymphoma, which affects the white blood cells that normally protect against illness, is categorized either as B-cell or T-cell. About 85% of lymphomas are of B-cell origin, and 15% of T-cell origin. T-cell lymphomas are primarily chronic, but they do not respond well to chemotherapy.

Therefore, says Arthur E. Frankel, M.D., director of the Research Institute and director of Scott & White's Division of hematology/oncology, the need exists to find new agents that can selectively target and kill the malignant T-cells. The research agent under study at Scott & White contains diphtheria targeting malignant T-cells.

"This new targeted protein agent is designed to eliminate tumor cells resistant to chemotherapy," said Dr. Frankel. "The short course of treatment may improve quality of life if successful."

To date, 10 people have enrolled in the clinical trial. Scott & White's CRI will enroll up to 40 subjects to participate in this clinical trial to determine the safest doses for treatment of T-cell . Eligible subjects for the study must have failed previous treatment options.

T-cell malignant diseases include MF/Sezary Syndrome, T-cell LGL, PTCL, T-cell CLL, T-cell NHL, angioimmunoblastic T-cell lymphoma, T-cell anaplastic large cell lymphoma, nasal extranodal T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and hepatosplenic T-cell lymphoma.

Explore further: Skin cancer rates five times higher than in 70s

Provided by Scott & White Healthcare

not rated yet
add to favorites email to friend print save as pdf

Related Stories

News from Cancer: Risk factors for deadly form of lymphoma

Jul 07, 2008

A new study indicates that the incidence of mantle cell lymphoma, an aggressive type of non-Hodgkin's lymphoma, is on the rise, most frequently striking men, Caucasians and older individuals. The study, published in the August ...

Recommended for you

Phase 3 study may be game-changer for acute myeloid leukemia

1 hour ago

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

User comments : 0

More news stories

Rising role seen for health education specialists

(HealthDay)—A health education specialist can help family practices implement quality improvement projects with limited additional financial resources, according to an article published in the March/April ...

FDA proposes first regulations for e-cigarettes

The federal government wants to prohibit sales of electronic cigarettes to minors and require approval for new products and health warning labels under regulations being proposed by the Food and Drug Administration.

When things get glassy, molecules go fractal

Colorful church windows, beads on a necklace and many of our favorite plastics share something in common—they all belong to a state of matter known as glasses. School children learn the difference between ...

FCC to propose pay-for-priority Internet standards

The Federal Communications Commission is set to propose new open Internet rules that would allow content companies to pay for faster delivery over the so-called "last mile" connection to people's homes.

SK Hynix posts Q1 surge in net profit

South Korea's SK Hynix Inc said Thursday its first-quarter net profit surged nearly 350 percent from the previous year on a spike in sales of PC memory chips.

Brazil enacts Internet 'Bill of Rights'

Brazil's president signed into law on Wednesday a "Bill of Rights" for the digital age that aims to protect online privacy and promote the Internet as a public utility by barring telecommunications companies ...